Why is this study being conducted?
The purpose of this study is to evaluate a potential new influenza vaccine in comparison to the current recommended influenza vaccine. The new vaccine contains an additional component that aims to give more protection against influenza.
Who is eligible to participate in this study?
You may be eligible if you:
- Are over 18 years of age
- Have not been vaccinated against influenza this year (2024)
- Are able to attend all scheduled study visits
Applicants who express interest in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?
Trial duration will be 22 days and participants will have about 2 trial visits.
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
You will receive a vaccine at the first study visit.
You will have 1 safety phone call.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for their time and travel associated with each study visit.
Contact Ting Yu
To learn more about this clinical trial, please contact:
Ting Yu, Clinical Trial Coordinator.
07 5678 0112 clinicaltrialunit@griffith.edu.au
This study has been approved by Bellberry Limited #2024-03-375 and GU HREC #2024/435.
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials